<DOC>
	<DOCNO>NCT01610297</DOCNO>
	<brief_summary>This prospective , single-arm , multicenter , national , phase II clinical study . The purpose Phase II study examine safety efficacy deferasirox decrease iron overload ( IOL ) posttransplant period patient beta-thalassemia major .</brief_summary>
	<brief_title>Post Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Inclusion Criteria Patients hematopoietic stem cell transplantation ( HSCT ) betathalassemia major hematopoietic stem cell transplantation ( HSCT ) perform minimum 6 month maximum 2 year ago The washout period immunosuppressive therapy least 3 month . Signifacant IOL present include : A. Serum ferritin &gt; 1000 μg/L B. cardiac MRI &lt; 20 m C. liver iron concentration ≥ 5 mg/g dry weight measure R2* MRI Exclusion Criteria Patients contraindication treatment deferasirox accord prescribe information •Patients depend transfusion Patients clinical symptom cardiac dysfunction ( shortness breath rest exertion , orthopnea , exercise intolerance , low extremity edema , arrhythmia ) Patients experience severe complication HSCT e.g . acute Graftversus host disease ( GVHD ) Significant proteinuria / Increase serum creatinine</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>hematopoietic stem cell transplantation , beta-thalassemia major , deferasirox , iron overload</keyword>
</DOC>